



(51) International Patent Classification:

C07D 249/10 (2006.01) **A61K 31/421** (2006.01)
C07D 263/34 (2006.01) **A61K 31/4245** (2006.01)
C07D 271/06 (2006.01) **A61K 31/433** (2006.01)
C07D 271/10 (2006.01) **A61P 9/00** (2006.01)
C07D 277/32 (2006.01) **A61P 11/00** (2006.01)
C07D 285/08 (2006.01) **A61P 37/00** (2006.01)
C07D 307/68 (2006.01) **A61P 25/28** (2006.01)
A61K 31/341 (2006.01) **A61P 29/00** (2006.01)
A61K 31/4196 (2006.01) **A61P 13/00** (2006.01)

(21) International Application Number:

PCT/EP2012/064628

(22) International Filing Date:

25 July 2012 (25.07.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11305971.1 26 July 2011 (26.07.2011) EP

(71) Applicant (for all designated States except US): **SANOFI**
[FR/FR]; 54 rue La Boétie, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RUF, Sven [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **PERNERSTORFER, Josef** [AT/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **SADOWSKI, Thorsten** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **HORSTICK, Georg** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **SCHREUDER, Herman** [NL/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BUNING, Christian** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WIRTH,**

Klaus [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(74) Agent: THEN, Johann; K 801, Sanofi-Aventis Deutschland GmbH, Patents Germany, Industriepark Höchst, Geb. K 801, 65926 Frankfurt am Main (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS



(57) Abstract: The present invention relates to compounds of the formula I, wherein Ht, G, R¹⁰, R³⁰, R⁴⁰, R⁵⁰ and R⁶⁰ have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

